Compugen Ltd. - CGEN Income before deduction of interest, taxes and amortization
The stability of Compugen Ltd. (CGEN) depends on partner payments and early test outcomes, which creates a financial deficit. EBITDA helps assess the issuer's real strength, where 0.00 serves as the current value of the parameter. Business growth is fueled by the AI platform and the alliance with Gilead, although protein synthesis relies entirely on external contractors.
Compugen - analytical breakdowns and key metrics (CGEN)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
CGEN - Net Income|Future Net Profit Compugen Ltd.|CGEN - P/E Multiple|Future Price to Earnings Multiple Compugen Ltd|CGEN - PEG Multiple|Company Value to EBITDA Compugen|CGEN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Compugen|CGEN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth cgen.com|CGEN - Earnings per share growth in current year|Net earnings per share change forecast for next year Compugen Ltd.
Analysis of all company metrics:Compugen Ltd. - CGEN
Compugen Ltd. is scaling its immuno-oncology developments by leveraging advanced computing platforms to create innovative drugs. An analysis of daily cash inflows from core operations on GURU.Markets allows for a real-time assessment of the liquidity behind this growth, while cash-equivalent operating profit helps investors promptly detect flow stagnation or the risk of overpaying for the asset.
Competitors of Compugen Ltd. (CGEN)
NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization iobiotech.com (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|Gritstone Bio - Operating profit EBITDA|kinetabio.com (KA) - Operating profit before deduction of amortization|NexImmune (NEXI) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Turnstone Biologics Corp. (TSBX)|Profit before payment of interest, taxes and amortization Vaccinex, Inc|Operating profit before deduction of amortization Harpoon Therapeutics Corp (HARP)
